This review summarized the occurrence of irAEs in breast cancer patients treated with PD-1/PD-L1 inhibitors in combination therapies and concluded options and strategies for counteracting and attenuating immune-related toxicities, aiming at providing physicians with guidance and recommendations for immunotherapy safety management of breast cancer. This evidence concerns the gene CD274 and breast carcinoma.